The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

benzothiazol     benzothiazole

Synonyms: benzthiazole, BENZOTHIAZOLE, Vangard BT, SureCN8430, AGN-PC-00JZ7S, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of benzothiazole

 

Psychiatry related information on benzothiazole

 

High impact information on benzothiazole

  • Using this method, a total of 25 benzothiazole derivatives that inhibit huntingtin fibrillogenesis in a dose-dependent manner were discovered from a library of approximately 184,000 small molecules [7].
  • Through extensive screening of a chemical library, we found that a benzothiazole compound, TG003, had a potent inhibitory effect on the activity of Clk1/Sty [8].
  • The intestinal lumen of EHBRs and Bcrp1 (-/-) mice was perfused with medium containing 4-methylumbelliferone (4MU) and E3040 [6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridilmethyl) benzothiazole] to determine the efflux of metabolites into the outflow [9].
  • The portion of the interface of TcTIM that binds the benzothiazole derivative and its equivalent region in human TIM differs in amino acid composition and hydrophobic packing [10].
  • We investigated the biodistribution and radiation dosimetry of the PET amyloid imaging agent (11)C-PIB ((11)C-6-OH-BTA-1) (where BTA is benzothiazole) in humans [11].
 

Chemical compound and disease context of benzothiazole

 

Biological context of benzothiazole

 

Anatomical context of benzothiazole

  • The biphasic dose-response relationship characteristically shown by the benzothiazole series against sensitive cell lines was exhibited by the 4- and 6-fluoro-benzothiazoles (10b,d) but not by the 5- and 7-fluoro-benzothiazoles (10h,i) [22].
  • Posttreatment with lubeluzole, the S-isomer of a novel 3,4-difluoro benzothiazole, potently rescued tactile/proprioceptive hindlimb placing reactions contralateral to unilateral thrombotic infarcts in the hindlimb area of the parietal sensorimotor neocortex of rats [23].
  • Here, we report the discovery and synthesis of a series of novel benzothiazole derivatives and their inhibitory activities against 11beta-HSD1 from human hepatic microsomes measured using a radioimmunoassay (RIA) method [24].
  • A series of structurally novel benzothiazole based small molecule inhibitors of p56(lck) was prepared to elucidate their structure-activity relationships (SAR), selectivity and cell activity in the T-cell proliferation assay [25].
  • In vitro results indicate primary cultures of brain cells are less sensitive to benzothiazole than epithelial cell lines [26].
 

Associations of benzothiazole with other chemical compounds

 

Gene context of benzothiazole

  • Previous findings have indicated that cytochrome P450 1A1 (CYP1A1) may play a role in the antitumour activity of molecules in the benzothiazole series including the nonfluorinated parent compound 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) (Kashiyama et al, 1999; Chua et al, 2000; Loaiza-Pérez et al, 2002) [32].
  • The results confirmed observations that P450 metabolizing isoforms, CYP1A1 and CYP1B1, are overexpressed in MCF-7 tumor cells following treatment with benzothiazole [33].
  • Conclusion: These data suggest that the anti-cancer activity of 5F 203 depends upon targets other than top1 or top2 and on the ability of this benzothiazole to form single-strand breaks and DNA-protein cross-links in cancer cells [34].
  • Present results point out that, besides the very well-known bi- and ter-benzimidazoles, compounds with single bicycle fused ring systems in their structure such as benzimidazole, benzoxazole, benzothiazole, and/or oxazolopyridine derivatives also exhibit significant topoisomerase II inhibitory activity [35].
  • The purpose of the present study is to investigate whether Bcrp1 could be involved in the urinary excretion of the human BCRP substrates, 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole sulfate (E3040S) and 4-methylumbelliferone sulfate (4MUS), using Bcrp1(-/-) mice [36].
 

Analytical, diagnostic and therapeutic context of benzothiazole

References

  1. ACD6, a novel ankyrin protein, is a regulator and an effector of salicylic acid signaling in the Arabidopsis defense response. Lu, H., Rate, D.N., Song, J.T., Greenberg, J.T. Plant Cell (2003) [Pubmed]
  2. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Loaiza-Pérez, A.I., Trapani, V., Hose, C., Singh, S.S., Trepel, J.B., Stevens, M.F., Bradshaw, T.D., Sausville, E.A. Mol. Pharmacol. (2002) [Pubmed]
  3. Long-range (1)H-(15)N heteronuclear shift correlation at natural abundance: a tool to study benzothiazole biodegradation by two rhodococcus strains. Besse, P., Combourieu, B., Boyse, G., Sancelme, M., De Wever, H., Delort, A.M. Appl. Environ. Microbiol. (2001) [Pubmed]
  4. S14080, a peripheral analgesic acting by release of an endogenous circulating opioid-like substance. Ferreira, S.H., Lorenzetti, B.B., Devissaguet, M., Lesieur, D., Tsouderos, Y. Br. J. Pharmacol. (1995) [Pubmed]
  5. In vitro cytotoxicity of Phortress against colorectal cancer. Mukherjee, A., Martin, S.G. Int. J. Oncol. (2006) [Pubmed]
  6. Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils. LeVine, H. Arch. Biochem. Biophys. (1997) [Pubmed]
  7. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Heiser, V., Engemann, S., Bröcker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S., Herhaus, C., Barnickel, G., Böttcher, H., Lehrach, H., Wanker, E.E. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  8. Manipulation of alternative splicing by a newly developed inhibitor of Clks. Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K., Yomoda, J., Murray, M.V., Kimura, H., Furuichi, K., Shibuya, H., Krainer, A.R., Suzuki, M., Hagiwara, M. J. Biol. Chem. (2004) [Pubmed]
  9. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Adachi, Y., Suzuki, H., Schinkel, A.H., Sugiyama, Y. Mol. Pharmacol. (2005) [Pubmed]
  10. Inactivation of triosephosphate isomerase from Trypanosoma cruzi by an agent that perturbs its dimer interface. Téllez-Valencia, A., Olivares-Illana, V., Hernández-Santoyo, A., Pérez-Montfort, R., Costas, M., Rodríguez-Romero, A., López-Calahorra, F., Tuena De Gómez-Puyou, M., Gómez-Puyou, A. J. Mol. Biol. (2004) [Pubmed]
  11. Biodistribution and Radiation Dosimetry of the Amyloid Imaging Agent 11C-PIB in Humans. Scheinin, N.M., Tolvanen, T.K., Wilson, I.A., Arponen, E.M., N??gren, K.A., Rinne, J.O. J. Nucl. Med. (2007) [Pubmed]
  12. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Mukherjee, A., Westwell, A.D., Bradshaw, T.D., Stevens, M.F., Carmichael, J., Martin, S.G. Br. J. Cancer (2005) [Pubmed]
  13. Benzothiazole degradation by Rhodococcus pyridinovorans strain PA: evidence of a catechol 1,2-dioxygenase activity. Haroune, N., Combourieu, B., Besse, P., Sancelme, M., Reemtsma, T., Kloepfer, A., Diab, A., Knapp, J.S., Baumberg, S., Delort, A.M. Appl. Environ. Microbiol. (2002) [Pubmed]
  14. Ranking of allergenic potency of rubber chemicals in a modified local lymph node assay. De Jong, W.H., Van Och, F.M., Den Hartog Jager, C.F., Spiekstra, S.W., Slob, W., Vandebriel, R.J., Van Loveren, H. Toxicol. Sci. (2002) [Pubmed]
  15. Heterocyclic benzazole derivatives with antimycobacterial in vitro activity. Kocí, J., Klimesová, V., Waisser, K., Kaustová, J., Dahse, H.M., Möllmann, U. Bioorg. Med. Chem. Lett. (2002) [Pubmed]
  16. Effect of CGP 20376 on Brugia malayi and parasite antigenemia in jirds. Chandrashekar, R., Subrahmanyam, D., Weil, G.J. J. Parasitol. (1991) [Pubmed]
  17. Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin. Stevens, M.F., McCall, C.J., Lelieveld, P., Alexander, P., Richter, A., Davies, D.E. J. Med. Chem. (1994) [Pubmed]
  18. Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability. Borthwick, A.D., Davies, D.E., Ertl, P.F., Exall, A.M., Haley, T.M., Hart, G.J., Jackson, D.L., Parry, N.R., Patikis, A., Trivedi, N., Weingarten, G.G., Woolven, J.M. J. Med. Chem. (2003) [Pubmed]
  19. Synthesis and structure-activity relationships of peptidyl alpha-keto heterocycles as novel inhibitors of prolyl endopeptidase. Tsutsumi, S., Okonogi, T., Shibahara, S., Ohuchi, S., Hatsushiba, E., Patchett, A.A., Christensen, B.G. J. Med. Chem. (1994) [Pubmed]
  20. Solution structure of a DNA complex with the fluorescent bis-intercalator TOTO determined by NMR spectroscopy. Spielmann, H.P., Wemmer, D.E., Jacobsen, J.P. Biochemistry (1995) [Pubmed]
  21. Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes. Bansal, V.S., Vaidya, S., Somers, E.P., Kanuga, M., Shevell, D., Weikel, R., Detmers, P.A. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  22. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. Hutchinson, I., Chua, M.S., Browne, H.L., Trapani, V., Bradshaw, T.D., Westwell, A.D., Stevens, M.F. J. Med. Chem. (2001) [Pubmed]
  23. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. De Ryck, M., Keersmaekers, R., Duytschaever, H., Claes, C., Clincke, G., Janssen, M., Van Reet, G. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  24. Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Su, X., Vicker, N., Ganeshapillai, D., Smith, A., Purohit, A., Reed, M.J., Potter, B.V. Mol. Cell. Endocrinol. (2006) [Pubmed]
  25. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors. Das, J., Moquin, R.V., Lin, J., Liu, C., Doweyko, A.M., DeFex, H.F., Fang, Q., Pang, S., Pitt, S., Shen, D.R., Schieven, G.L., Barrish, J.C., Wityak, J. Bioorg. Med. Chem. Lett. (2003) [Pubmed]
  26. In vivo and in vitro effects of benzothiazole on sheepshead minnow (Cyprinodon variegatus). Evans, J.J., Shoemaker, C.A., Klesius, P.H. Mar. Environ. Res. (2000) [Pubmed]
  27. Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives. Mylari, B.L., Zembrowski, W.J., Beyer, T.A., Aldinger, C.E., Siegel, T.W. J. Med. Chem. (1992) [Pubmed]
  28. Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone. Costanzo, M.J., Yabut, S.C., Almond, H.R., Andrade-Gordon, P., Corcoran, T.W., De Garavilla, L., Kauffman, J.A., Abraham, W.M., Recacha, R., Chattopadhyay, D., Maryanoff, B.E. J. Med. Chem. (2003) [Pubmed]
  29. Alterations in tau phosphorylation in rat and human neocortical brain slices following hypoxia and glucose deprivation. Burkhart, K.K., Beard, D.C., Lehman, R.A., Billingsley, M.L. Exp. Neurol. (1998) [Pubmed]
  30. Mechanism of thioflavin T binding to amyloid fibrils. Khurana, R., Coleman, C., Ionescu-Zanetti, C., Carter, S.A., Krishna, V., Grover, R.K., Roy, R., Singh, S. J. Struct. Biol. (2005) [Pubmed]
  31. Solution structure of a DNA complex with the fluorescent bis-intercalator TOTO modified on the benzothiazole ring. Petersen, M., Jacobsen, J.P. Bioconjug. Chem. (1998) [Pubmed]
  32. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Trapani, V., Patel, V., Leong, C.O., Ciolino, H.P., Yeh, G.C., Hose, C., Trepel, J.B., Stevens, M.F., Sausville, E.A., Loaiza-Pérez, A.I. Br. J. Cancer (2003) [Pubmed]
  33. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. Wallqvist, A., Monks, A., Rabow, A.A., Thanki, N., Shoemaker, R.H., Covell, D.G. Progress in cell cycle research. (2003) [Pubmed]
  34. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Brantley, E., Antony, S., Kohlhagen, G., Meng, L., Agama, K., Stinson, S.F., Sausville, E.A., Pommier, Y. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  35. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors. Pinar, A., Yurdakul, P., Yildiz, I., Temiz-Arpaci, O., Acan, N.L., Aki-Sener, E., Yalcin, I. Biochem. Biophys. Res. Commun. (2004) [Pubmed]
  36. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Mizuno, N., Suzuki, M., Kusuhara, H., Suzuki, H., Takeuchi, K., Niwa, T., Jonker, J.W., Sugiyama, Y. Drug Metab. Dispos. (2004) [Pubmed]
  37. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. Wang, Y., Klunk, W.E., Debnath, M.L., Huang, G.F., Holt, D.P., Shao, L., Mathis, C.A. J. Mol. Neurosci. (2004) [Pubmed]
  38. Fine-structure alterations in female Brugia malayi and Litomosoides carinii after in vivo treatment with flubendazole. Franz, M., Zahner, H., Benten, P. Parasitol. Res. (1990) [Pubmed]
  39. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles. Goldfarb, R.H., Kitson, R.P., Brunson, K.W., Yoshino, K., Hirota, N., Kirii, Y., Kotera, Y., Inoue, Y., Ohashi, M. Anticancer Res. (1999) [Pubmed]
 
WikiGenes - Universities